US11452309B2 - Formula of preparations for oral and/or enteral feeding of children - Google Patents

Formula of preparations for oral and/or enteral feeding of children Download PDF

Info

Publication number
US11452309B2
US11452309B2 US16/479,119 US201816479119A US11452309B2 US 11452309 B2 US11452309 B2 US 11452309B2 US 201816479119 A US201816479119 A US 201816479119A US 11452309 B2 US11452309 B2 US 11452309B2
Authority
US
United States
Prior art keywords
kynurenic acid
children
preparations
content
milk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US16/479,119
Other versions
US20190387782A1 (en
Inventor
Piotr Paluszkiewicz
Pawel Milart
Waldemar Turski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62908548&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US11452309(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of US20190387782A1 publication Critical patent/US20190387782A1/en
Application granted granted Critical
Publication of US11452309B2 publication Critical patent/US11452309B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea

Definitions

  • the subject of the invention is a new and improved formula for the oral and enteral feeding of children and offspring of mammals characterised by the fact that the preparations contain kynurenic acid or its salt at a concentration adapted to its content in the breast milk at different times from birth.
  • the composition of substitute foods is designed to deviate in the minimum amount possible from the composition of the nursing mother's breast milk. According to data from the World Health Organization, only 38% of children are breastfed by mothers. Approximately 800,000 infant deaths caused by suboptimal feeding are recorded annually, including due to the use of mixtures replacing the mother's breast milk. Despite the progress in research on the composition of milk provided by nursing mothers, it was considered that the optimal solution is to introduce a policy promoting natural feeding and the goal is to reach a percentage of 50% of children fed by mothers in a natural way by 2025. This policy is a response to the insufficient progress in the development of new nutrient mixtures, which can replace natural human breast milk.
  • kynurenic acid is present in the human breast milk in varying amounts, dependent on the time elapsed since delivery. It was stated that the concentration of kynurenic acid in milk increases with time.
  • Kynurenic acid is a metabolite of tryptophan formed on the kynurenine pathway. It occurs in the tissues and body fluids in the human body and in other mammals. It is absorbed from the gastrointestinal tract and reaches high levels in the blood and tissues (Kuc et al. Amino Acids. 2008, 35: 503-5).
  • Kynurenic acid has an effect on glutamate receptors, such as the N-methyl-D-aspartic (NMDA) receptor, the kainate receptor, and the ⁇ -amino-3-hydroxy-5-methyl-4-isoxazole-propionic (AMPA) receptor.
  • Kynurenic acid is an antagonist of the nicotinic alpha-7 receptor (Kemp et al. Proc Natl Acad Sci USA, 1988, 85: 6547-50; Hilmas et al. J Neurosci, 2001, 21: 7463-73).
  • GPR35 receptor Wang et al. 2006, J Biol Chem, 281: 22021-8)
  • the AHR receptor DiNatale et al. 2010, Toxicol Sci. 2010; 115:89-97.
  • the GPR35 and AHR receptors are particularly abundantly present in the gastrointestinal tract.
  • Kynurenic acid is known to inhibit the development of oxidative stress and prevent lipid peroxidation in intestinal obstruction (Kaszaki et al. Neurogastroenterol Motil, 2008, 20, 53-62). Kynurenic acid also has an analgesic effect (Nasstróm et al. Eur J Pharmacol, 1992, 212, 21-9).
  • Kynurenic acid and its derivatives are used for the preparation of medicaments used in the treatment of disease states with increased intestinal peristalsis (Kaszaki et al. Neurogastroenterol Motil, 2008, 20, 53-62), and also in gout and multiple sclerosis (WO/2008/087461). Kynurenic acid is also effective in the treatment of septic shock (WO/2006/117624).
  • kynurenic acid occurs in plants, including herbs for medical applications (Zgrajka et al., Ann Agric Environ Med. 2013; 20: 800-2) and in food, mainly of vegetable origin (Turski et al., Amino Acids. 2009; 36:75-80) and does not show any toxic effects (Turski et al., Pharmacol Rep. 2014; 66:1127-33) it was examined what the content of this substance is in known preparations for oral feeding of children. It was unexpectedly found that none of the producers indicates the presence of kynurenic acid in their product. In professional literature, there is no information on the content of kynurenic acid in preparations used for children's nutrition.
  • Milk from 25 breastfeeding mothers was used for testing. Each mother provided a sample of 10 ml of fresh milk independently drawn by the nursing mother into a sterile test tube. Milk samples were taken from each mother 6 times on the third day, after one week, two weeks, one month, three months and six months after physiological labour.
  • Standard formulas intended for oral feeding of infants up to 6 months of age were obtained commercially. Three packages of a commercial preparation were used for the study from each of the three analysed different series specified by the manufacturer on the packaging.
  • the 0.1 ml of 2 M perchloric acid was added to every 0.5 ml of human breast milk samples and centrifuged for 15 minutes at 6000 rpm. The obtained supernatant was stored at ⁇ 20° C. to determine the concentration of kynurenic acid.
  • Samples of formulas intended for feeding infants up to 6 months of age were prepared in accordance with the recipe provided by the manufacturer. Perchloric acid was added to liquid formula samples and the mixture was centrifuged like milk from nursing mothers. The obtained supernatant was used for further determinations.
  • the supernatant was acidified with 2 M trichloric acid.
  • the denatured proteins were separated by centrifugation and the obtained deproteinized supernatant was suspended in 1 M hydrochloric acid.
  • the obtained deproteinized supernatant was applied to ion-exchange columns (Dowex 50W+, 200-400 mesh) filled with 0.1 M hydrochloric acid. The columns were washed with 1 ml 0.1 M HCl and 1 ml of deionized water. The obtained eluate was chromatographed (HPLC). The quantitative determination of kynurenic acid was carried out using the metric fluoride technique.
  • the kynurenic acid standard was obtained from Sigma-Aldrich (St. Louis, USA). All reagents used to determine the kynurenic acid concentration came from the producers providing the highest degree of purity.
  • the average kynurenic acid content is very diverse and ranges from 0.03 to 1.08 ⁇ g/100 ml depending on the type of preparation, while the average content of kynurenic acid in breast milk on the third day after delivery is 0.39 ⁇ g/100 ml, on day 6, 1.07 ⁇ g/100 ml, at week 2, 2.11 ⁇ g/100 ml and week 4, 3.74 ⁇ g/100 ml.
  • These amounts are significantly different from the amount of kynurenic acid in commercial preparations.
  • the average content of kynurenic acid is 0.38 to 0.58 ⁇ g/100 ml depending on the type of preparation, while the average content of kynurenic acid in breast milk at 3 months after delivery is 4.15 ⁇ g/100 ml. This amount exceeds the amount of kynurenic acid in commercial preparations more than 10 times.
  • the average kynurenic acid content is very diverse and ranges from 0.29 to 1.42 ⁇ g/100 ml depending on the type of preparation, while the average content of kynurenic acid in breast milk at 6 months after delivery is 5.66 ⁇ g/100 ml. This amount is much higher than the amount of kynurenic acid in commercial preparations appropriate to the age (4-20 times).
  • the average kynurenic acid content is very diverse and ranges from 0.28 to 1.52 ⁇ g/100 ml depending on the type of preparation. These amounts are significantly lower than the average kynurenic acid content in mother's milk at 6 months after delivery, which is 5.66 ⁇ g/100 ml. This amount is much higher than the amount of kynurenic acid in commercial preparations appropriate to the age (4-20 times).
  • the solubility of kynurenic acid in water is 0.95 mg/ml (http://www.hmdb.ca/metabolites/HMDB00715).
  • Kynurenic acid is readily soluble in alkaline conditions; in 1.0 M NaOH, its solubility is 50 mg/ml (http://www4.mpbio.com/ecom/docs/proddata.nsf/440121766f8ee75e8525645d0068b043/2f736b869 41e7f61852569cb00688812? OpenDocument).
  • kynurenic acid which are well soluble in water, e.g. a sodium salt, with the solubility of 100 mM (http://www.abcam.com/kynurenic-acid-sodium-salt-ab120256.html), which corresponds to a solubility of 21 mg/ml.
  • kynurenic acid in powder form was added to the children's powder formula—Bebilon Nenatal in an amount corresponding to 10 times the highest content of kynurenic acid found in breast milk of 13.78 ⁇ g/100 ml (Table 1), that is 137.8 ⁇ g/100 ml converted into the volume recommended by the manufacturer. Then water was added in the amount recommended by the manufacturer and the whole was mixed well.
  • Macroscopic examination proved that the addition of kynurenic acid did not change the colour, consistency and pH of the mixture, compared to the control mixture, without the addition of kynurenic acid.
  • kynurenic acid dissolved in water was added to the finished liquid preparation Bebilon 1.
  • the added amount of kynurenic acid corresponded to 10 times the highest content of kynurenic acid found in breast milk of 13.78 ⁇ g/ml (Table 1), that is 137.8 ⁇ g/100 ml.
  • the preparation for oral feeding of children is prepared by means known in the food industry, provided that the kynurenic acid content should preferably be 0.01-0.7 ⁇ g/100 ml for children 1-5 days; 0.8-1.6 ⁇ g/100 ml for children aged 6-14 days; 1.7-2.9 ⁇ g/100 ml for children aged 2-3 weeks; 3.0-3.9 ⁇ g/100 ml for children aged 4-12 weeks; 4.0-5.0 ⁇ g/100 ml for children aged 4-6 months; 5.1-14.0 ⁇ g/100 ml for children aged 7-12 months.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Pediatric Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The subject of the invention is a new and improved formula of preparations for the oral and enteral feeding of children and offspring of mammals, which cannot or should not be fed by the mother, characterized by the fact, that the preparations contain kynurenic acid or its salt at a concentration adapted to its content in the mother's natural milk at different times from delivery.

Description

CROSS-REFERENCE TO RELATED APPLICATION
This application is a Section 371 National Stage Application of International Application No. PCT/PL2018/000006, filed Jan. 16, 2018, and published as W02018/135957A1 on Jul. 26, 2018, which claims priority to and benefits of Polish Patent Application Serial No. P.420258, filed with the Patent Office of the Republic of Poland on Jan. 20, 2017, the entire contents of which are incorporated herein by reference.
The subject of the invention is a new and improved formula for the oral and enteral feeding of children and offspring of mammals characterised by the fact that the preparations contain kynurenic acid or its salt at a concentration adapted to its content in the breast milk at different times from birth.
The correct development of the child (including postnatal maturation of various organs and systems) is to a large extent dependent on a balanced supply of food understood as a biologically active mixture of basic nutrients, minerals, vitamins, and substances found in trace amounts, responsible for enabling a bridging transition between the prenatal period and the intake of solid foods. In developmental physiology, it is assumed that the ideal composition of the mixture is provided in the human breast milk which composition changes with the development of the fed baby. The inability of the mother to feed her baby due to the lack of lactation, diseases of the mammary glands (lactic in animals) or dysfunctions of the newborn which prevent natural feeding, requires the use of special feeding techniques such as enteral nutrition by a gastric tube (nutritional fistula), or the provision of substitute food. The composition of substitute foods is designed to deviate in the minimum amount possible from the composition of the nursing mother's breast milk. According to data from the World Health Organization, only 38% of children are breastfed by mothers. Approximately 800,000 infant deaths caused by suboptimal feeding are recorded annually, including due to the use of mixtures replacing the mother's breast milk. Despite the progress in research on the composition of milk provided by nursing mothers, it was considered that the optimal solution is to introduce a policy promoting natural feeding and the goal is to reach a percentage of 50% of children fed by mothers in a natural way by 2025. This policy is a response to the insufficient progress in the development of new nutrient mixtures, which can replace natural human breast milk.
Additionally, it is emphasised that natural feeding by mothers plays a significant role in reducing the risk of diseases in adulthood, such as obesity, diabetes and asthma (WHO Global Targets 2025, www.who.int).
When conducting research on the development of the gastrointestinal tract, it was unexpectedly found that kynurenic acid is present in the human breast milk in varying amounts, dependent on the time elapsed since delivery. It was stated that the concentration of kynurenic acid in milk increases with time.
Kynurenic acid is a metabolite of tryptophan formed on the kynurenine pathway. It occurs in the tissues and body fluids in the human body and in other mammals. It is absorbed from the gastrointestinal tract and reaches high levels in the blood and tissues (Kuc et al. Amino Acids. 2008, 35: 503-5).
Kynurenic acid has an effect on glutamate receptors, such as the N-methyl-D-aspartic (NMDA) receptor, the kainate receptor, and the α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic (AMPA) receptor. Kynurenic acid is an antagonist of the nicotinic alpha-7 receptor (Kemp et al. Proc Natl Acad Sci USA, 1988, 85: 6547-50; Hilmas et al. J Neurosci, 2001, 21: 7463-73). In addition, it affects the GPR35 receptor (Wang et al. 2006, J Biol Chem, 281: 22021-8) and the AHR receptor (DiNatale et al. 2010, Toxicol Sci. 2010; 115:89-97). The GPR35 and AHR receptors are particularly abundantly present in the gastrointestinal tract.
Kynurenic acid is known to inhibit the development of oxidative stress and prevent lipid peroxidation in intestinal obstruction (Kaszaki et al. Neurogastroenterol Motil, 2008, 20, 53-62). Kynurenic acid also has an analgesic effect (Nasstróm et al. Eur J Pharmacol, 1992, 212, 21-9).
The protective effect of kynurenic acid against gastric ulcers is also known (Glavin et al. Prog Neuropsychopharmacol Biol Psychiatry. 1989; 13(3-4):569-72, Res Commun Chem Pathol Pharmacol. 1989; 64:111-9).
Kynurenic acid and its derivatives are used for the preparation of medicaments used in the treatment of disease states with increased intestinal peristalsis (Kaszaki et al. Neurogastroenterol Motil, 2008, 20, 53-62), and also in gout and multiple sclerosis (WO/2008/087461). Kynurenic acid is also effective in the treatment of septic shock (WO/2006/117624).
Because kynurenic acid occurs in plants, including herbs for medical applications (Zgrajka et al., Ann Agric Environ Med. 2013; 20: 800-2) and in food, mainly of vegetable origin (Turski et al., Amino Acids. 2009; 36:75-80) and does not show any toxic effects (Turski et al., Pharmacol Rep. 2014; 66:1127-33) it was examined what the content of this substance is in known preparations for oral feeding of children. It was unexpectedly found that none of the producers indicates the presence of kynurenic acid in their product. In professional literature, there is no information on the content of kynurenic acid in preparations used for children's nutrition. Our own research indicated that in the currently manufactured preparations, the amount of kynurenic acid is very diverse and only in some preparations intended for children up to 6 days of age approaches the physiological quantities of kynurenic acid during this period. In addition, it has been determined that that the amount of kynurenic acid in modern preparations for children's nutrition is not controlled in a planned manner and is accidental. It probably results from the use of various natural ingredients in the preparation process. On this basis, it can be stated that the presence of kynurenic acid in current preparations for child nutrition can be regarded as accidental “contamination”. In view of the well-defined biological effect of kynurenic acid and the fact that its content in the natural milk of breastfeeding women varies in depending on the time, an improved composition of preparations intended for children's nutrition was proposed, in which natural changes in the content of kynurenic acid in breast milk were taken into account.
EXAMPLES
Material Human Breast Milk
Milk from 25 breastfeeding mothers was used for testing. Each mother provided a sample of 10 ml of fresh milk independently drawn by the nursing mother into a sterile test tube. Milk samples were taken from each mother 6 times on the third day, after one week, two weeks, one month, three months and six months after physiological labour.
Formulas Intended for the Oral Feeding of Infants
Standard formulas intended for oral feeding of infants up to 6 months of age were obtained commercially. Three packages of a commercial preparation were used for the study from each of the three analysed different series specified by the manufacturer on the packaging.
Methods
The 0.1 ml of 2 M perchloric acid was added to every 0.5 ml of human breast milk samples and centrifuged for 15 minutes at 6000 rpm. The obtained supernatant was stored at −20° C. to determine the concentration of kynurenic acid.
Samples of formulas intended for feeding infants up to 6 months of age were prepared in accordance with the recipe provided by the manufacturer. Perchloric acid was added to liquid formula samples and the mixture was centrifuged like milk from nursing mothers. The obtained supernatant was used for further determinations.
The supernatant was acidified with 2 M trichloric acid. The denatured proteins were separated by centrifugation and the obtained deproteinized supernatant was suspended in 1 M hydrochloric acid.
The obtained deproteinized supernatant was applied to ion-exchange columns (Dowex 50W+, 200-400 mesh) filled with 0.1 M hydrochloric acid. The columns were washed with 1 ml 0.1 M HCl and 1 ml of deionized water. The obtained eluate was chromatographed (HPLC). The quantitative determination of kynurenic acid was carried out using the metric fluoride technique. The kynurenic acid standard was obtained from Sigma-Aldrich (St. Louis, USA). All reagents used to determine the kynurenic acid concentration came from the producers providing the highest degree of purity.
Results
Example 1
The Concentration of Kynurenic Acid in the Human Breast Milk
As a result of the research, an increasing concentration of kynurenic acid in the human breast milk was found depending on the time elapsed from delivery. The average concentration of kynurenic acid in breast milk on the third day after delivery was 14 times lower than the average concentration after 6 months of breastfeeding (Table 1). The observed differences were statistically significant from the 14th day after delivery compared to the content on the 3rd day.
TABLE 1
The concentration of kynurenic acid (μg/100 ml) in the human
breast milk depending on the time passed since the delivery.
Time passed since the delivery
3 × 24 6 × 24 2 4 3 6
hours hours weeks weeks months months
arithmetic 0.39 1.07 2.11 3.74 4.15 5.66
mean
SD 0.34 1.26 1.79 2.28 2.68 3.34
SEM 0.06 0.23 0.34 0.45 0.55 0.86
Median 0.30 0.59 1.70 2.99 3.16 5.18
Min 0.00 0.00 0.34 0.45 0.37 0.83
Max 1.53 4.88 9.24 10.36 11.03 13.78
ANOVA NS p <0.01 p <0.001 p <0.001 p <0.001
Dunn
post-hoc test
SD - standard deviation;
SEM - standard error of the mean;
min - lowest;
max - the highest measurement value
Example 2
The concentration of kynurenic acid in commercial preparations of milk intended for feeding newborns, infants and older children
No producer specifies the content of kynurenic acid in the formulations they produce. The conducted tests revealed the presence of kynurenic acid in all tested milk preparations intended for feeding infants (Table 2). As a result of the analyses performed, no differences were found in kynurenic acid content in the tested preparations depending on the packaging from the same manufacturer's series. There were significant differences between the preparations of different manufacturers. The largest difference concerned NAN AR (0.03 μg/100 ml) and Bebilon 1 immuno fortis (1.08 μg/100 ml), indicating a 36-fold difference in the amount of kynurenic acid (Table 2).
TABLE 2
The average content of kynurenic acid (μg/100 ml) in commercial preparations of milk
intended for feeding to children depending on the feeding period recommended by the producer.
since 4 since 6 since 9-10 since 12 since 24
Feeding period since birth months months months months months
NAN AR 0.03
NAN pro HA 1 liquid 0.07
NAN HA 1 0.09
Bebilon 1 HA immuno fortis 0.21
NAN Active 1 0.24
Bebiko HA 1 0.25
NAN 1 0.25
NAN Pro 1 liquid 0.31
Bebilon Pepti liquid 0.33
Bebilon 1 immuno fortis 0.33
comfort
Bebilon pepti 1 0.35
NAN AR 0.37
Bebilon 1 liquid 0.44
Bebilon AR 1 0.63
Nutramigen 1 0.66
Enfamil Premium 1 0.67
Bebiko Nenatal Premium 0.85
Enfamil AR 1 0.89
Bebiko 1 0.93
HIPP BIO 1 1.03
Bebilon 1 immuno fortis 1.08
Bebilon PEPTI 2 0.38
Nutramigen 2 0.58
Bebilon HA 2 0.29
NAN HA 2 0.31
Bebiko HA 2 0.33
Bebilon comfort 2 0.47
NAN 2 0.54
Bebiko 2R 0.70
Bebiko 2 0.71
NAN 2 R 0.71
NAN 2 Active 0.74
Enfamil premium 2 0.80
NAN pro d.noc B 0.95
Bebilon 2 immuno fortis 0.99
Enfamil AR 2 1.19
HIPP BIO 2 1.42
NAN HA 3 0.28
NAN PRO 3 0.98
NAN 3R 1.08
HIPP BIO 3 1.52
Bebiko Junior 3 0.65
Bebilon Junior 3 1.18
Bebiko Junior 4 0.67
Bebilon Junior 4 1.03
The measurements were made in five milk packages and three different producer's series were compared (15 measurements for each tested preparation).
A comparison of series of the same commercial preparations of milk intended for child nutrition showed significant differences in the content of kynurenic acid. The discrepancy between the series reached twice the amount of kynurenic acid calculated per 100 ml of the preparation intended for children (Table 3).
TABLE 3
The concentration of kynurenic acid (μg/100 ml) in the tested milk
preparations intended for feeding children with the indication
of the series with the lowest and highest kynurenic acid content.
Loose preparations Average SD SEM Min. Max.
Bebilon 1 Immuno 0.33 0.12 0.07 0.20 0.45
fortis comfort
Bebilon AR 1 0.64 0.12 0.07 0.51 0.77
Bebilon Junior 3 1.18 0.04 0.02 1.1 1.22
Bebilon Junior 4 1.03 0.02 0.01 1.01 1.05
Bebilon Pepti 2 0.38 0.08 0.05 0.33 0.47
Bebilon 1 Immuno fortis 1.08 0.16 0.09 0.98 1.27
Bebilon 2 Immuno fortis 0.99 0.36 0.21 0.7 1.4
Bebilon 1 HA 0.21 0.05 0.03 0.18 0.28
Immuno fortis
Bebilon HA 2 0.29 0.02 0.01 0.28 0.31
Bebilon Comfort 2 0.47 0.27 0.16 0.3 0.78
Bebilon Pepti 1 0.35 0.05 0.03 0.31 0.41
Bebilon Nenatal 0.85 0.29 0.16 0.64 1.18
premium
Bebiko 1 0.93 0.13 0.08 0.83 1.08
Bebiko 2 0.71 0.02 0.01 0.69 0.73
Bebiko 2R 0.7 0.07 0.04 0.63 0.77
Bebiko HA 1 0.25 0.01 0.01 0.23 0.27
Bebiko HA 2 0.32 0.03 0.02 0.29 0.36
Bebiko Junior 3 0.65 0.05 0.03 0.58 0.69
Bebiko Junior 4 0.66 0.02 0.01 0.65 0.68
Enfamil Premium 1 0.67 0.09 0.05 0.60 0.77
Enfamil Premium 2 0.80 0.07 0.04 0.72 0.84
Enfamil AR 1 0.89 0.07 0.04 0.83 0.96
Enfamil AR 2 1.19 0.31 0.18 0.95 1.54
HIPP Bio 1 1.03 0.05 0.03 0.99 1.08
HIPP Bio 2 1.42 0.03 0.02 1.38 1.45
HIPP Bio 3 1.52 0.23 0.13 1.28 1.74
NAN 1 0.25 0.03 0.02 0.22 0.27
NAN 2 0.54 0.10 0.06 0.43 0.64
NAN HA 1 0.09 0.02 0.01 0.07 0.12
NAN HA 2 0.31 0.10 0.06 0.19 0.40
NAN HA 3 0.28 0.08 0.04 0.21 0.36
NAN AR 0.37 0.14 0.08 0.24 0.53
NAN Active 1 0.24 0.05 0.03 0.20 0.30
NAN Active 2 0.73 0.07 0.05 0.68 0.78
NAN PRO d.night B 0.95 0.14 0.08 0.77 1.05
NAN PRO 3 0.98 0.05 0.03 0.93 1.03
NAN 2 R 0.71 0.37 0.21 0.33 1.06
NAN 3 R 1.08 0.11 0.02 1.08 1.08
Nutramigen 1 0.66 0.36 0.20 0.42 1.07
hypoallergenic
Nutramigen 2 0.58 0.16 0.09 0.43 0.76
hypoallergenic
Liquid preparations Average SD SEM Min. Max.
Bebilon Nenatal 0.74 0.02 0.01 0.72 0.75
premium
Bebilon Pepti liquid 0.33 0.03 0.02 0.29 0.35
Bebilon 1 0.44 0.08 0.05 0.39 0.53
NAN PRO 1 0.31 0.04 0.02 0.29 0.36
NAN PRO HA 1 0.07 0.01 0.01 0.06 0.07
Enfamil Premium 1 0.51 0.02 0.01 0.49 0.53
SD-standard deviation;
SEM-standard error of the mean;
Min-average minimum value in the series;
Max-average maximum value in the series
Example 3
Comparison of Kynurenic Acid Concentration in Commercial Preparations of Milk Intended for Child Nutrition with the Concentration in Human Breast Milk at the Same Time After Delivery
In commercial preparations of milk intended for child nutrition in the period from birth, the average kynurenic acid content is very diverse and ranges from 0.03 to 1.08 μg/100 ml depending on the type of preparation, while the average content of kynurenic acid in breast milk on the third day after delivery is 0.39 μg/100 ml, on day 6, 1.07 μg/100 ml, at week 2, 2.11 μg/100 ml and week 4, 3.74 μg/100 ml. These amounts are significantly different from the amount of kynurenic acid in commercial preparations. There are also significant differences in the content of kynurenic acid between preparations from different production series. In addition, commercial preparations intended for children of this age contain a constant amount of kynurenic acid, whereas the content of kynurenic acid in breast milk increases almost 4 times in 4 weeks, from 0.39 μg/100 ml to 3.74 μg/100 ml. None of the products reflects the dynamics of changes in kynurenic acid content during this period.
In commercial preparations of milk intended for children from 4 months of age, the average content of kynurenic acid is 0.38 to 0.58 μg/100 ml depending on the type of preparation, while the average content of kynurenic acid in breast milk at 3 months after delivery is 4.15 μg/100 ml. This amount exceeds the amount of kynurenic acid in commercial preparations more than 10 times.
In commercial preparations of milk intended for child nutrition in the period from 6 months of age, the average kynurenic acid content is very diverse and ranges from 0.29 to 1.42 μg/100 ml depending on the type of preparation, while the average content of kynurenic acid in breast milk at 6 months after delivery is 5.66 μg/100 ml. This amount is much higher than the amount of kynurenic acid in commercial preparations appropriate to the age (4-20 times).
In commercial preparations of milk intended for child nutrition in the period from 9-24 months of age, the average kynurenic acid content is very diverse and ranges from 0.28 to 1.52 μg/100 ml depending on the type of preparation. These amounts are significantly lower than the average kynurenic acid content in mother's milk at 6 months after delivery, which is 5.66 μg/100 ml. This amount is much higher than the amount of kynurenic acid in commercial preparations appropriate to the age (4-20 times).
Example 4
The Preparation Method of Formula for Oral Feeding of Children
The solubility of kynurenic acid in water is 0.95 mg/ml (http://www.hmdb.ca/metabolites/HMDB00715).
Kynurenic acid is readily soluble in alkaline conditions; in 1.0 M NaOH, its solubility is 50 mg/ml (http://www4.mpbio.com/ecom/docs/proddata.nsf/440121766f8ee75e8525645d0068b043/2f736b869 41e7f61852569cb00688812? OpenDocument).
There are salts of kynurenic acid which are well soluble in water, e.g. a sodium salt, with the solubility of 100 mM (http://www.abcam.com/kynurenic-acid-sodium-salt-ab120256.html), which corresponds to a solubility of 21 mg/ml.
The results of our own research in the light of data from the literature indicate that the solubility of kynurenic acid in water is sufficient to obtain the highest recommended concentration of this substance which results from the determination of the physiological content of kynurenic acid in the milk of breast-feeding women. The solubility of kynurenic acid of 0.95 mg/ml is 6900 times higher than the highest content of kynurenic acid in the mother's milk tested in the study, which is 13.78 μg/100 ml (Table 1), which allows the production of a preparation with an increased content of kynurenic acid in comparison to physiological contents. For this purpose, a well-soluble kynurenic acid salt or kynurenic acid dissolved in alkali may also be used.
Because kynurenic acid is soluble in water, kynurenic acid in powder form was added to the children's powder formula—Bebilon Nenatal in an amount corresponding to 10 times the highest content of kynurenic acid found in breast milk of 13.78 μg/100 ml (Table 1), that is 137.8 μg/100 ml converted into the volume recommended by the manufacturer. Then water was added in the amount recommended by the manufacturer and the whole was mixed well.
Macroscopic examination proved that the addition of kynurenic acid did not change the colour, consistency and pH of the mixture, compared to the control mixture, without the addition of kynurenic acid.
As nutritional preparations are available in ready liquid form, kynurenic acid dissolved in water was added to the finished liquid preparation Bebilon 1. The added amount of kynurenic acid corresponded to 10 times the highest content of kynurenic acid found in breast milk of 13.78 μg/ml (Table 1), that is 137.8 μg/100 ml.
Macroscopic examination proved that the addition of kynurenic acid did not change the colour, consistency and pH of the mixture, compared to the control mixture, without the addition of kynurenic acid. Conclusions: The preparation for oral feeding of children is prepared by means known in the food industry, provided that the kynurenic acid content should preferably be 0.01-0.7 μg/100 ml for children 1-5 days; 0.8-1.6 μg/100 ml for children aged 6-14 days; 1.7-2.9 μg/100 ml for children aged 2-3 weeks; 3.0-3.9 μg/100 ml for children aged 4-12 weeks; 4.0-5.0 μg/100 ml for children aged 4-6 months; 5.1-14.0 μg/100 ml for children aged 7-12 months.
SUMMARY
    • 1. Human breast milk contains kynurenic acid in an increasing amount with breastfeeding time. Concentrations of kynurenic acid in milk of breastfeeding women are 14 times higher in the 6th month of feeding compared to 3 days after delivery.
    • 2. The content of kynurenic acid in the majority of preparations for children's nutrition is significantly lower compared to the content of kynurenic acid in the milk of breast-feeding women. Only commercial preparations with the highest content of kynurenic acid contain kynurenic acid in the amount similar to the content in milk of women on day 6 of breastfeeding.
    • 3. The content of kynurenic acid in infant preparations is accidental, i.e. it is not deliberately planned by the manufacturer and is not controlled.
    • 4. The research results argue in favour of the development of a preparation refined formula intended for feeding children and offspring of mammals taking into account natural changes in the content of kynurenic acid in breast milk of women and lactating animals.
    • 5. In order to obtain the desired effect of kynurenic acid, the content of kynurenic acid in infant preparations should preferably be 0.01-0.7 μg/100 ml for children aged 1-5 days; 0.8-1.6 μg/100 ml for children aged 6-14 days; 1.7-2.9 μg/100 ml for children aged 2-3 weeks; 3.0-3.9 μg/100 ml for children aged 4-12 weeks; 4.0-5.0 μg/100 ml for children aged 4-6 months; 5.1-14.0 μg/100 ml for children aged 7-12 months.
    • 6. Due to the sufficiently good solubility of kynurenic acid in water ensuring its content at the physiological level, kynurenic acid or its soluble salt may be used to prepare the formula for feeding children and offspring of mammals in a loose form, or a solution of kynurenic acid or a salt thereof for preparation in a liquid form.

Claims (4)

The invention claimed is:
1. A nutritional composition for the oral and enteral feeding of children comprising kynurenic acid or its salt designed for a child 4-12 weeks, wherein kynurenic acid or a salt thereof is present, in an amount of 3.0-3.9 μg/100 ml.
2. A nutritional composition for the oral and enteral feeding of children comprising kynurenic acid or its salt designed for a child aged 4-6 months, wherein kynurenic acid or a salt thereof is present, in an amount of 4.0-5.0 μg/100 ml.
3. A nutritional composition for the oral and enteral feeding of children comprising kynurenic acid or its salt designed for a child aged 7-12 months, wherein kynurenic acid or a salt thereof is present, in the amount of 5.1-14.0 μg/100 ml.
4. A nutritional composition for the oral and enteral feeding of children comprising kynurenic acid or its salt designed for a child aged 3 weeks, wherein kynurenic acid or a salt thereof is present in an amount of 1.7-2.9 μg/100 ml.
US16/479,119 2017-01-20 2018-01-16 Formula of preparations for oral and/or enteral feeding of children Active 2038-09-05 US11452309B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PL420258A PL234411B1 (en) 2017-01-20 2017-01-20 Improved formula of preparations for oral and enteral nutrition of children
PL420258 2017-01-20
PLP.420258 2017-01-20
PCT/PL2018/000006 WO2018135957A1 (en) 2017-01-20 2018-01-16 Improved formula of preparations for oral and/or enteral feeding of children

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/PL2018/000006 A-371-Of-International WO2018135957A1 (en) 2017-01-20 2018-01-16 Improved formula of preparations for oral and/or enteral feeding of children

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/890,801 Continuation US20220386673A1 (en) 2017-01-20 2022-08-18 Formula of preparations for oral and/or enteral feeding of children

Publications (2)

Publication Number Publication Date
US20190387782A1 US20190387782A1 (en) 2019-12-26
US11452309B2 true US11452309B2 (en) 2022-09-27

Family

ID=62908548

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/479,119 Active 2038-09-05 US11452309B2 (en) 2017-01-20 2018-01-16 Formula of preparations for oral and/or enteral feeding of children
US17/890,801 Pending US20220386673A1 (en) 2017-01-20 2022-08-18 Formula of preparations for oral and/or enteral feeding of children

Family Applications After (1)

Application Number Title Priority Date Filing Date
US17/890,801 Pending US20220386673A1 (en) 2017-01-20 2022-08-18 Formula of preparations for oral and/or enteral feeding of children

Country Status (10)

Country Link
US (2) US11452309B2 (en)
EP (1) EP3573482B1 (en)
JP (1) JP7360326B2 (en)
ES (1) ES2906578T3 (en)
HU (1) HUE057651T2 (en)
IL (1) IL268088B2 (en)
PL (2) PL234411B1 (en)
PT (1) PT3573482T (en)
WO (1) WO2018135957A1 (en)
ZA (1) ZA201905340B (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006117624A2 (en) 2005-04-29 2006-11-09 Universita'degli Studi Di Firenze Kynurenic acid and salts thereof for the prevention and treatment of shock
WO2008087461A2 (en) 2007-01-17 2008-07-24 Szegedi Tudományegyetem Use of kynurenic acid and derivatives thereof in the treatment of conditions of the gastrointestinal tract accompanied by hypermotility and inflammation or gout or multiple sclerosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6265442B1 (en) * 1990-09-13 2001-07-24 The General Hospital Corporation Treatment of neurological diseases by increasing brain concentrations of kynurenic acid
JPH0564542A (en) * 1991-09-03 1993-03-19 Meiji Milk Prod Co Ltd Standardized milk for infant rearing enriched in bile salt activating lipase
JP3238009B2 (en) * 1993-06-14 2001-12-10 雪印乳業株式会社 Infant formula
JP2015173607A (en) 2014-03-13 2015-10-05 日本澱粉工業株式会社 Modified milk powder containing 1,5-anhydro-D-glucitol
RU2761533C2 (en) 2014-09-25 2021-12-09 Сосьете Де Продюи Нестле С.А. Infant formula system with adaptive concentrations of breast milk oligosaccharides (bmo)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006117624A2 (en) 2005-04-29 2006-11-09 Universita'degli Studi Di Firenze Kynurenic acid and salts thereof for the prevention and treatment of shock
WO2008087461A2 (en) 2007-01-17 2008-07-24 Szegedi Tudományegyetem Use of kynurenic acid and derivatives thereof in the treatment of conditions of the gastrointestinal tract accompanied by hypermotility and inflammation or gout or multiple sclerosis

Non-Patent Citations (22)

* Cited by examiner, † Cited by third party
Title
Buttar, H.S et al.: "Evaluation of the antioxidant properties of tryptophan and its metabolites in in vitro assai" Journal of Complementary & Integrative Medicine (Jun. 1, 2016) vol. 13, No. 2, pp. 129-136 (Abstract).
Cruz, M., et al. "Urinary excretion of metabolites of the tryptophan-kynurenine pathway in healthy infants after an oral loading dose of L-tryptophan" Revista Espanola de Fisiologia (1972), 28(4), pp. 283-286 (Abstract).
DiNatale et al. "Kynurenic Acid Is a Potent Endogenous Aryl Hydrocarbon Receptor Ligand that Synergistically Induces Interleukin-6 in the Presence of Inflammatory Signaling" 2010, Toxicol Sci. 2010; 115:89-97.
Glavin et al. "Kynurenic acid attenuates experimental ulcer formation and basal gastric acid secretion in rats" Res Commun Chem Pathol Pharmacol Apr. 1989; 64(1):111-119.
Glavin et al. "Kynurenic acid protects against gastroduodenal ulceration in mice injected with extracts from poisonous atlantic shellfish" Prog Neuropsychopharmacol Biol Psychiatry. 1989; 13(3-4):569-72, Res Commun Chem Pathol Pharmacol. 1989;64:111-9.
Hilmas et al. "The Brain Metabolite Kynurenic Acid Inhibits α7 Nicotinic Receptor Activity and Increases Non-α7 Nicotinic Receptor Expression: Physiopathological Implications" J Neurosci, 2001, 21: 7463-7473.
Hottinger, A. et al. "The excretion of xanthurenic acid and kynurenic acid after a tryptophan load" Internationale Zeitschrift fuer Vitaminforschung (1963), 34(1), 99. 81-8 (Abstract).
International Preliminary Report on Patentability issued for PCT/PL2018/000006, dated Jul. 23, 2019.
International Search Report issued for PCT/PL2018/000006, dated May 14, 2018.
Kaszaki et al. "Kynurenic acid inhibits intestinal hypermotility and xanthine oxidase activity during experimental colon obstruction in dogs" Neurogastroenterol Motil, 2008, 20, 53-62.
Kemp et al. "7Chlorokynurenic acid is a selective antagonist at the glycine modulatory site of the N-methyl-D-aspartate receptor complex" Proc Natl Acad Sci USA, 1988, 85: 6547-6550.
Kuc et al. "Micromolar concentration of kynurenic acid in rat small intestine" Amino Acids. 2008, 35: 503-5).
Nasstrom et al. "Antinociceptive actions of different classes of excitatory amino acid receptor antagonists in mice" Eur J Pharmacol, 1992, 212, 21-9.
O'Rourke L. et al. "The Relationship Between Maternal Tryptophan Metabolism, Cytokines and Cortisol in Term and Preterm Expressed Breast Milk" 2014 Pediatric Academic Societies and Asian Society for Pediatric Research Joint Meeting in Vancouver, BC, Canada, May 3-6 Retrieved from http://undergraduatelibrary.org/system/files/1251.pdf.
Search Report issued in PL patent application No. 420258, dated Aug. 9, 2017.
Turski et ai. "Presence of kynurenic acid in food and honeybee products" Amino Acids. 2009; 36: 75-80.
Turski et al. "On the toxicity of kynurenic acid in vivo and in vitro" Pharmacol Rep. 2014;66:1127-1133.
Turski, M.P. et al. "Kynurenic Acid in the Digestive System—New Facts, New Challenges" Int J Tryptophan Res. Sep. 4, 2013;6:47-55.
Walczak, K.: "Nowe aspekty aktywnosci biologicznej kwasu kynureninowego, produktu katabolizmu tryptofanu" Medycyna Ogolna, 2009, 15 (XLIV), 4, p. 566-575.
Wang et al. "Kynurenic Acid as a Ligand for Orphan G Protein-coupled Receptor GPR35" 2006, J Biol Chem, 281:22021-22028.
Written Opinion of International Searching Authority issued for PCT/PL2018/000006, dated May 14, 2018.
Zgrajka et al. "Kynurenic acid content in anti-rheumatic herbs" Ann Agric Environ Med. 2013; 20: 800-802.

Also Published As

Publication number Publication date
PT3573482T (en) 2022-03-07
WO2018135957A1 (en) 2018-07-26
IL268088B (en) 2022-10-01
EP3573482A4 (en) 2021-01-27
PL234411B1 (en) 2020-02-28
EP3573482B1 (en) 2021-12-01
US20190387782A1 (en) 2019-12-26
EP3573482A1 (en) 2019-12-04
PL3573482T3 (en) 2022-04-04
PL420258A1 (en) 2018-07-30
JP7360326B2 (en) 2023-10-12
HUE057651T2 (en) 2022-05-28
IL268088A (en) 2019-09-26
ES2906578T3 (en) 2022-04-19
IL268088B2 (en) 2023-02-01
US20220386673A1 (en) 2022-12-08
JP2020505384A (en) 2020-02-20
ZA201905340B (en) 2020-09-30

Similar Documents

Publication Publication Date Title
JP2025122083A (en) Compositions and methods for treating or preventing metabolic fatigue using the compound oleuropein or its metabolites
CN103250892B (en) Buffalo calf starter feed
US20120077780A1 (en) Fat Accumulation Inhibitor and Method of Use Thereof
US10806170B2 (en) Heat sterilized high protein compositions comprising whey protein and at least one component selected from (i) a saccharide, (ii) a phosphate and (iii) a citrate
JP2007246404A (en) Learning ability-improving agent
US8791065B2 (en) Low-concentration nutritional composition
US11452309B2 (en) Formula of preparations for oral and/or enteral feeding of children
KR101133944B1 (en) Nutrient composition and composition for prevention/mitigation of digestive tract depression
CN109123102A (en) A kind of aseptic experiment mouse feed and preparation method thereof
DK1776956T3 (en) An agent for the prevention and / or treatment of calcium deficiency
JP2004115509A (en) Osteoprotegerin inhibitory factor production promoter
NL2015032B1 (en) Compositions and methods for the treatment of malnutrition.
JP2007070343A (en) Sleep inducer, stress insomnia improving agent
JP2018519322A (en) Marine peptides and muscle health
JP2017171595A (en) Bdnf production promoting agent
RU2450825C2 (en) Using leptin for preventing overweight and compositions containing leptin
CN110200086A (en) A kind of fat or oil composition
RU2471364C1 (en) 1-6-month old calves feeding method envisaging mineral premix introduction into ration
Mehta Efficacy of amino acids, vitamins, minerals, docosahexaenoic acid, galactagogue combination on lactation: A postmarketing surveillance study
CN108378237A (en) Piglet prescription milk preparation method
JP7181695B2 (en) Antidementia agent and short-term memory impairment improver/suppressor
JP6525265B2 (en) Artificial milk for elephant
RU2639450C1 (en) Method for feeding of infants with mucoviscidosis
US20230354836A1 (en) Infant formula composition and methods of manufacture
CN119817810A (en) Formula food with special medical application and preparation method and application thereof

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: ADVISORY ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 4